Pfizer delayed its myocarditis safety study for under-21s from 2024 to 2030, raising fears of data suppression amid evidence linking mRNA vaccines to heart inflammation. The study’s narrow seven-day case window may underestimate risks. Critics say the delay undermines transparency, while independent studies confirm elevated myocarditis in young males. FDA warnings have strengthened, but Pfizer’s postponed results fuel concerns over vaccine safety and accountability.
HIGHLY CORRUPT Pfizer hides MYOCARDITIS study results to protect false vaccine safety claims.
